Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Stage III Colon Cancer AJCC V8: early-phase trial registry

2 of 8 indexed Stage III Colon Cancer AJCC V8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Stage III Colon Cancer AJCC V8: 8 US clinical trials tracked, 2 recruiting.

Stage III Colon Cancer AJCC V8 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition stage-iii-colon-cancer-ajcc-v8

OPEN 2 | RECR 25% | LATE 1 | EARLY 6 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Stage III Colon Cancer A (th…25%
Open-enrollment share among volume-matched conditions near Stage III Colon Cancer AJCC V8

Stage III Colon Cancer AJCC V8 lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage III Colon Cancer AJCC V8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage III Colon Cancer AJCC V8 is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage III Colon Cancer AJCC V8 research.

    M.D. Anderson Cancer Center accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage III Colon Cancer AJCC V8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Stage III Colon Cancer AJCC V8 research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

8 total, page 1 of 1

RECRUITING NA 70 participants

Designing a Dyad-Based MHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers

Ohio State University Comprehensive Cancer Center

NCT06746012

RECRUITING Phase 2 40 participants

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Emory University

NCT07140679

ACTIVE NOT RECRUITING Phase 3 712 participants

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

NCT02912559

ACTIVE NOT RECRUITING Phase 2 84 participants

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

NCT05308446

ACTIVE NOT RECRUITING Phase 1 51 participants

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

M.D. Anderson Cancer Center

NCT04599140

ACTIVE NOT RECRUITING Phase 1 46 participants

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

NCT04616183

ACTIVE NOT RECRUITING Phase 2 12 participants

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Academic and Community Cancer Research United

NCT03992456

ACTIVE NOT RECRUITING Phase 2 1 participants

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Alliance for Clinical Trials in Oncology

NCT05710406

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Stage III Colon Cancer AJCC V8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Biological
3 trials
Computed Tomography Procedure
3 trials
Biospecimen Collection Procedure
3 trials
Encorafenib Drug
2 trials
Nivolumab Biological
2 trials
Questionnaire Administration Other
2 trials
ERK1/2 Inhibitor LY3214996 Drug
1 trials
Trifluridine and Tipiracil Hydrochloride Drug
1 trials

US sites by state

Facility locations filed on Stage III Colon Cancer AJCC V8 trials. A trial with sites in several states counts in each.

Texas 3 trials
Georgia 3 trials
California 3 trials
Arizona 3 trials
Wisconsin 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage III Colon Cancer AJCC V8 page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Colon Cancer AJCC V8 condition card totals 8 registered trials; most-linked intervention Cetuximab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.